Topics

Tumor Mutational Burden Predicts for Response to Immuotherapy in NSCLC

07:11 EDT 12 Jul 2019 | Cancer Connect

Research suggests that tumor mutational burden assessment can help predict response to immunotherapy in NSCLC.

Original Article: Tumor Mutational Burden Predicts for Response to Immuotherapy in NSCLC

NEXT ARTICLE

More From BioPortfolio on "Tumor Mutational Burden Predicts for Response to Immuotherapy in NSCLC"

Quick Search

Relevant Topic

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...